Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. (MLYS) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
mlys · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Mineralys Therapeutics, Inc. (MLYS) measures how much investors pay for each dollar of the company's trailing earnings. MLYS's current PE ratio of N/A is calculated by dividing its stock price of $22.50 by its TTM earnings per share of -$1.83.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2020 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Mineralys Therapeutics, Inc.You MLYS | $1.5B | N/A | — | -$1.83 |
 Adaptive Biotechnologies Corporation ADPT | $2.7B | N/A | — | -$0.39 |
 Agios Pharmaceuticals, Inc. AGIO | $1.6B | N/A | — | -$7.12 |
 Apellis Pharmaceuticals, Inc. APLS | $5.3B | 141.40x | +82.8% | $0.18 |
 Beam Therapeutics Inc. BEAM | $3.1B | N/A | — | -$0.81 |
 Cidara Therapeutics, Inc. CDTX | $5.6B | N/A | — | -$26.75 |
 Catalyst Pharmaceuticals, Inc. CPRX | $3.8B | 13.32x | -82.8% | $1.75 |
Industry Average 2 peers with valid PE | — | 77.36x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-2.29 | — | |
2024-12-31 FY2024 | — | $-3.66 | — | |
2023-12-31 FY2023 | — | $-1.99 | — | |
2022-12-31 FY2022 | — | $-5.77 | — | |
2021-12-31 FY2021 | — | $-3.89 | — | |
2020-12-31 FY2020 | — | $-0.74 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Mineralys Therapeutics, Inc. (MLYS) measures how much investors pay for each dollar of the company's trailing earnings. MLYS's current PE ratio of N/A is calculated by dividing its stock price of $22.50 by its TTM earnings per share of -$1.83.
Frequently asked questions
MLYS pe ratio · 6 questionsMLYS's current PE ratio is N/A as of 2026-06-08, based on a stock price of $22.50 and TTM EPS of -$1.83. Data sourced from Financial Modeling Prep via MLYS's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Mineralys Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08